Hollis-Eden Pharmaceuticals (HEPH) Up 40%
Hollis-Eden (HEPH) and company in the development of a new class of small molecule compounds based on endogenous steroid hormones, today announced new preclinical data with its drug candidate HE3235 ...Read Full Story »

